Key facts
- Validose’s last known valuation is $6.0M (Jan 2025).
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($1.6M) in Dec 2024.
- Notable investors include Interstate Fusion Ventures, Bauer Family Office's Technology for Humanity, 10XBeta.
- Validose has filed 1 Form D with the SEC, most recently Jan 2025 ($1.6M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Validose
Funding rounds
1 roundsAbout Validose
Developer of an intranasal drug delivery platform designed to deliver medication adherence solutions for clinical trials in real-time. The company's platform integrates with care management, clinical study, and population health platforms and also covers a range of delivery methods, and works with any medical formulation, enabling doctors to enhance patient care with insight for trial management and provide quality care to patients.
- Sector
- Healthcare
- HQ
- Brooklyn, NY, United States
- Founded
- 2017
- Employees
- 5
- Website
- validose.com/
- Ownership
- Privately Held (backing)
Validose doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Validose shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Validose in its N-PORT filings yet. We sweep new filings monthly.